Chemotherapy treatment for older women with metastatic breast cancer: What is the evidence?

Cancer Treatment Reviews

Volumn 37, Issue 8, 2011, Pages 590-598

  Debled, Marc ^a   Bellera, Carine ^a   Donamaria, Catherine ^a   Soubeyran, Pierre ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Chemotherapy; Clinical trials; Elderly; External validity; Generalizibility; Metastatic breast carcinoma; Review

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXIFLURIDINE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IDARUBICIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PIRARUBICIN; UFT;

AGE DISTRIBUTION; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; DRUG TOXICITY; HUMAN; METASTASIS; REVIEW;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PATIENT SELECTION; QUALITY OF LIFE; REVIEW LITERATURE AS TOPIC;

EID: 80054087634     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.04.007     Document Type: Review

References (64)

1. Altekruse SF, Kosary CL, Krapcho M, et al. in: Edwards BK, Bethesda, MD (eds), SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. , based on November 2009 SEER data submission, posted to the SEER web site, 2010. http://www.seer.cancer.gov/csr/1975_2007.
2. Nationalatlas. http://www.nationalatlas.gov.
3. Smith B.D., Smith G.L., Hurria A., Hortobagyi G.N., Buchholz T.A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009, 27:2758-2765.
4. Rothwell P.M. External validity of randomised controlled trials: " to whom do the results of this trial apply?" Lancet 2005, 365:82-93.
5. D'hondt R., Paridaens R., Wildiers H., et al. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 2004, 15:341-346.
6. Hainsworth J.D., Burris H.A., Yardley D.A., et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001, 19:3500-3505.
7. Nicolella D., Grimaldi G., Colantuoni G., et al. Weekly low dose epirubicin in elderly cancer patients. Tumori 1996, 82:369-371.
8. Cascinu S., Del Ferro E., Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 1996, 19:371-374.
9. Feher O., Vodvarka P., Jassem J., et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 2005, 16:899-908.
10. Mlineritsch B., Schabel-Moser R., Andel J., et al. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 2009, 32:18-24.
11. Vogel C., O'Rourke M., Winer E., et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999, 10:397-402.
12. Morris D.M., Gross D.C., Edwards J. Preoperative chemotherapy is beneficial for geriatric patients with locally advanced and metastatic breast cancer. J La State Med Soc 1990, 142:27-31.
13. Tashiro H., Mashino K., Shibahara K., et al. The efficacy and safety of docetaxel for elderly advanced breast cancer patients. Gan To Kagaku Ryoho 2007, 34:453-455.
14. Gelman R.S., Taylor S.G. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984, 2:1404-1413.
15. Taylor S.G., Gelman R.S., Falkson G., et al. Combination chemotherapy compared to Tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 1986, 104:455-461.
16. Ibrahim N.K., Frye D.K., Buzdar A.U., Walters R.S., Hortobagyi G.N. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 1996, 156:882-888.
17. Ibrahim N.K., Hortobagyi G.N., Ewer M., et al. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the MD Anderson experience. Cancer Chemother Pharmacol 1999, 43:471-478.
18. Repetto L., Simoni C., Venturino A., et al. Mitoxantrone in elderly women with advanced breast cancer: a phase II study. Anticancer Res 1995, 15:2297-2300.
19. Kurtz J.E., Rousseau F., Meyer N., et al. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients. Oncology 2007, 73:210-214.
20. Crivellari D., Lombardi D., Corona G., et al. Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. Ann Oncol 2006, 17:807-812.
21. Baweja M., Suman V.J., Fitch T.R., et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients 65 years of age: an NCCTG study. Ann Oncol 2006, 17:623-629.
22. Bajetta E., Procopio G., Celio L., et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005, 23:2155-2161.
23. Perez E.A., Vogel C.L., Irwin D.H., Kirshner J.J., Patel R. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 2002, 73:85-88.
24. Hess D., Koberle D., Thurlimann B., et al. Capecitabine and vinorelbine as first-line treatment in elderly patients (65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology 2007, 73:228-237.
25. Hess D., Thürlimann B., Pagani O., et al. Capecitabine and vinorelbine in elderly patients (65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 2004, 15:1760-1765.
26. Basso U., Fratino L., Brunello A., et al. Which benefit from adding gemcitabine to vinorelbine in elderly (70 years) women with metastatic breast cancer? Early interruption of a phase II study. Ann Oncol 2007, 18:58-63.
27. Sorio R., Robieux I., Galligioni E., et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997, 33:301-303.
28. Addeo R., Faiola V., Guarrasi R., et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women 65 years of age. Cancer Chemother Pharmacol 2008, 62:285-292.
29. Del Mastro L., Perrone F., Repetto L., et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005, 16:253-258.
30. Freyer G., Lortholary A., Delcambre C., et al. Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience. Clin Oncol (R Coll Radiol) 2004, 16:17-23.
31. Debled M, Madranges N, Mertens C, et al. First-line chemotherapy for metastatic breast cancer in patients ≥75years. A retrospective single-centre analysis. Crit Rev Oncol Hematol 2010 [Epub ahead of print].
32. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Under-representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
33. Wyld L., Reed M.W.R. The need for targeted research into breast cancer in the elderly. Br J Surg 2003, 90:388-399.
34. Yee K.W., Pater J.L., Pho L., Zee B., Siu L.L. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?. J Clin Oncol 2003, 21:1618-1623.
35. Lewis J.H., Kilgore M.L., Goldman D.P., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003, 21:1383-1389.
36. Dekkers O.M., von Elm E., Algra A., Romijn J.A., Vandenbroucke J.P. How to assess the external validity of therapeutic trials: a conceptual approach. Int J Epidemiol 2010, 39:89-94.
37. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5:224-237.
38. Freyer G., Braud A.C., Chaibi P., et al. Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'. Ann Oncol 2006, 17:211-216.
39. Brain E, Girre V, Rigal O, et al. Screening success and inclusion failure rates in a prospective trial of adjuvant chemotherapy for breast cancer in elderly women by the French Geriatric Oncology Group GERICO. 35th ESMO Congress Mila, Italy, 8-12 october 2010. Ann Oncol 2010;31(suppl 8):86(272PD).
40. Zimmerman M., Chelminski I., Posternak M.A. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005, 162:1370-1372.
41. Pibouleau L., Boutron I., Reeves B.C., Nizard R., Ravaud P. Applicability and generalisability of published results of randomised controlled trials and non-randomised studies evaluating four orthopaedic procedures: methodological systematic review. BMJ 2009, 339:b4538.
42. Crivellari D., Aapro M., Leonard R., et al. Breast cancer in the elderly. J Clin Oncol 2007, 25:1882-1890.
43. Addeo R., Sgambato A., Cennamo G., et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 2010, 10:301-306.
44. Lorenzo I., Constenla M., Palacios P., et al. Docetaxel as single-agent treatment in elderly patients with advanced breast cancer. Clin Drug Investig 2005, 25:249-256.
45. Gupta S., Mauer A.M., Ryan C.W., Taber D.A., Samuels B.L., Fleming G.F. A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am J Clin Oncol 2005, 28:65-69.
46. Dinota A., Bilancia D., Romano R., Manzione L. Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer. Breast Cancer Res Treat 2005, 89:1-3.
47. Maisano R., Mare M., Caristi N., et al. A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study. J Chemother 2005, 17:242-246.
48. Massacesi C., Marcucci F., Boccetti T., et al. Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. J Exp Clin Cancer Res 2005, 24:43-48.
49. ten Tije A.J., Smorenburg C.H., Seynaeve C., et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004, 40:352-357.
50. Bajetta E., Biganzoli L., Carnaghi C., et al. Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer. Cancer 1998, 83:1136-1141.
51. Mammoliti S., Merlini L., Caroti C., Gallo L. Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. Breast Cancer Res Treat 1996, 37:93-96.
52. Gladieff L., Houyau P., Mihura J., et al. A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women. Bull Cancer 1996, 83:703-706.
53. Beex L.V., Hermus A.R., Pieters G.F., van Hoesel Q.G., Nooy M.A., Mignolet F. Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer. Eur J Cancer 1992, 28:686-690.
54. Chevallier B., Mignot L., Delozier T., Morvan F., Ferme C., Herait P. Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer. Am J Clin Oncol 1992, 15:395-398.
55. Chevallier B., Monnier A., Metz R., et al. Phase II study of oral idarubicin in elderly patients with advanced breast cancer. Am J Clin Oncol 1990, 13:436-439.
56. Repetto L., Comandini D., Mammoliti S., Pietropaolo M., Del Mastro L. Weekly paclitaxel in elderly patients with advanced breast cancer: a dose-finding study. Drugs RD 2004, 5:11-15.
57. Kurtz J.E., Deplanque G., Borel C., et al. Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. Ann Oncol 2000, 11:229-230.
58. Smorenburg C.H., ten Tije A.J., Verweij J., et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 2003, 39:196-202.
59. Repetto L., Vannozzi M.O., Balleari E., et al. Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoetic progenitor cells. Anticancer Res 1999, 19:879-884.
60. Biganzoli L., Coleman R., Minisini A., et al. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol 2007, 61:84-89.
61. Christman K., Muss H.B., Case L.D., Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA 1992, 268:57-62.
62. Kotsori A.A., Noble J.L., Ashley S., Johnston S., Smith I.E. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?. Breast 2010, 19:377-381.
63. Rossi A., Gridelli C., Gebbia V., et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 2003, 23:1657-1664.
64. Zaniboni A., Bolognesi A., Arnoldi E., Tabiadon D., Barni S., Intini C. Oral idarubicin and cyclophosphamide for metastatic breast cancer in elderly patients. Anticancer Drugs 1998, 9:295-299.